Author

Gray RT

November 14, 2018
Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake – a modeling study
Summary Subsidized direct-acting antiviral (DAA) treatment recently became available to all adults living with chronic hepatitis C (HCV) in Australia. Based on rapid uptake (32,600 people initiated DAA in 2016) we estimated the impact on HCV epidemiology and mortality in Australia and determined if Australia can meet the WHO HCV elimination targets by 2030. Using […]

Read More
January 30, 2017
Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment
Summary Background and aim Interferon-free direct-acting antiviral regimens for hepatitis C virus (HCV) infection have been recently available in Australia, beginning a new era in clinical and public health management of HCV infection. This study provided updated estimates of the HCV infection care cascade and burden in Australia as a reliable platform for assessing the […]

Read More